IV Dexamethasone

# IV dexamethasone ## Overview - **Classification**: Corticosteroid, Glucocorticoid - **Mechanism**: Potent anti-inflammatory and immunosuppressant. Suppresses leukocyte migration, reverses increased capillary permeability, and reduces prostaglandin/leukotriene synthesis. ## Primary Indications 1. **Cerebral Edema** - Associated with brain tumors, neurosurgery, or traumatic brain injury. 2. **Chemotherapy-Induced Nausea & Vomiting (CINV)** - Prevention and treatment. 3. **Acute Anti-inflammatory/Allergic Conditions** - Severe allergic reactions, asthma exacerbations. 4. **COVID-19** - For patients requiring supplemental oxygen or mechanical ventilation. ## Adult Dosing ### Standard Dosing **Cerebral Edema (from tumor)** - **Dose**: **10 mg** IV - **Frequency**: Once, then **4 mg** IV every 6 hours - **Route**: IV - **Duration**: Until resolution of symptoms or treatment of underlying cause. **Chemotherapy-Induced Nausea & Vomiting (CINV)** - **Dose**: **8-20 mg** IV (depending on emetogenicity) - **Frequency**: Single dose prior to chemotherapy - **Route**: IV **Acute Severe Allergic Reactions/Asthma Exacerbation** - **Dose**: **4-8 mg** IV - **Frequency**: Single dose, then potentially tapered oral dose - **Route**: IV **COVID-19 (requiring supplemental oxygen or ventilation)** - **Dose**: **6 mg** IV - **Frequency**: Once daily - **Route**: IV - **Duration**: For up to 10 days or until hospital discharge. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed. Dexamethasone is primarily metabolized by the liver. - **Hepatic Impairment**: Monitor closely. Dose reduction may be needed in severe impairment due to decreased metabolism. - **Elderly Patients**: No specific dose adjustment. Use lowest effective dose due to increased risk of adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Bronchopulmonary Dysplasia (BPD) prevention/treatment (short-term, highly selective use). - **Dose**: **0.05-0.1 mg/kg/dose** - **Frequency**: Every 12-24 hours - **Maximum**: Individualized based on clinical status - **Special Notes**: Use with extreme caution due to potential neurodevelopmental effects. ### Infants (1-12 months) - **Indication**: Croup (Laryngotracheobronchitis) - **Dose**: **0.15-0.6 mg/kg** (single dose) - **Frequency**: Once - **Maximum**: **10 mg** - **Special Notes**: Oral route often preferred if tolerated. ### Children (1-12 years) - **Indication**: Croup - **Dose**: **0.15-0.6 mg/kg** (single dose) - **Frequency**: Once - **Maximum**: **10 mg** - **Indication**: Anti-emetic (CINV) - **Dose**: **5-10 mg/m2** (or **5-20 mg** total) - **Frequency**: Single dose prior to chemotherapy - **Maximum**: **20 mg** ### Adolescents (13-18 years) - **Dose**: Typically follows **adult dosing** guidelines for most indications. - **Maximum**: Adult dose as appropriate for indication. ## Safety Information ### Contraindications - **Absolute**: Systemic fungal infections (untreated). - **Absolute**: Hypersensitivity to dexamethasone or its excipients. - **Relative**: Live or live-attenuated vaccines during immunosuppressive doses. - **Relative**: Active untreated infections (viral, bacterial, parasitic), ocular herpes simplex. ### Common Adverse Effects - **Very Common (>10%)**: Fluid retention, increased appetite, insomnia, mood changes (nervousness, euphoria). - **Common (1-10%)**: Hypertension, hyperglycemia, dyspepsia, muscle weakness, acne, skin thinning. - **Serious but Rare**: Adrenal suppression, Cushing's syndrome, GI perforation, severe infections, osteonecrosis, acute psychosis. ### Key Drug Interactions - **CYP3A4 Inducers (e.g., phenytoin, rifampin)**: Decreased dexamethasone levels. May require increased dexamethasone dose. - **CYP3A4 Inhibitors (e.g., azole antifungals, macrolides)**: Increased dexamethasone levels. May require decreased dexamethasone dose. - **NSAIDs**: Increased risk of GI ulceration/bleeding. Co-administer with caution. - **Antidiabetics**: Hyperglycemic effect. May require increased antidiabetic dose. - **Live Vaccines**: Contraindicated during immunosuppressive doses due to immunosuppression. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure, blood glucose, electrolytes (K), infection screen (if prolonged use anticipated). - **During Treatment**: Monitor blood pressure, blood glucose, electrolytes (K) (especially with prolonged use). Monitor for signs of infection. - **Clinical Signs**: Watch for fluid retention, changes in mood/behavior, signs of infection, GI upset, hyperglycemia. ## Clinical Pearls - 💡 **Administer slowly**: Rapid IV infusion can cause perineal burning/itching, especially with higher doses. Infuse over 1-5 minutes. - 💡 **Taper for prolonged use**: Do not abruptly discontinue after prolonged therapy (>7-10 days) to prevent adrenal insufficiency. Taper dose gradually. - 💡 **Timing of dose**: For once-daily dosing, administer in the morning to mimic natural cortisol rhythm and reduce insomnia. - 💡 **Diabetic patients**: Closely monitor blood glucose and adjust antidiabetic medications as needed during treatment. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.